Streetwise Reports (04/14/2026)
Replimune Group Inc.'s (REPL:NASDAQ) RP1 melanoma therapy hits FDA rejection, raising uncertainty around approval timelines and future market potential. Contributed Opinion
Michael Ballanger (04/14/2026)
Michael Ballanger of GGM Advisory Inc. shares his thoughts on the current state of the market and a few stocks he believes are worth looking into. Streetwise Reports (04/14/2026)
Copper Giant Resources Corp. (CGNT:TSXV; LBCMF:OTCQB) announces results from drilling at its Mocoa copper-molybdenum porphyry project in Colombia. Find out why two analysts recommend the stock. Streetwise Reports (04/14/2026)
Contango Silver & Gold Inc. says its common stock has been approved for listing on the Toronto Stock Exchange. Read why one has raised his target price. Research Report
Scott Searle (04/14/2026)
ROTH Capital Partners reiterated its rating on Adeia Inc. (ADEA:NASDAQ), citing accelerating hybrid bonding adoption in logic chiplets (AMD, Broadcom), 3D NAND (Kioxia, Sandisk), and HBM4e DRAM. Streetwise Reports (04/13/2026)
Vanguard Mining Corp. (UUU:CSE; UUUFF:OTC; SL51:FWB) announced a deal to acquire 100% of Quark Uranium Ltd. Streetwise Reports (04/13/2026)
Silver Crown Royalties Inc. (SCRI:CBOE; SLCRF:OTCQX; QS0:FSE) announced a CA$4.5 million private placement priced at a 5% premium to market. Streetwise Reports (04/13/2026)
MindBio Therapeutics Corp.'s (MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt) AI voice model analyzes 140+ biomarkers, targeting non-invasive impairment screening.